TauRx Completes US$135m Financing Round to Support Phase 3 Clinical Trials Program in Alzheimer’s and Frontotemporal Dementia
ABERDEEN, Scotland and SINGAPORE, 07 October 2015 – TauRx Pharmaceuticals Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer’s disease, today announced the completion of the final tranche of a US$135m equity financing that it launched in March.
With the publication of a key article in The Journal of Biological Chemistry, TauRx Pharmaceuticals Ltd. continues to build a growing body of evidence supporting the rationale for tau aggregation inhibition in the treatment of neurodegenerative diseases such as Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD). This latest of six connected papers, five of them published in the past six months, describes the robust scientific research programme behind the development of LMTX, the second-generation tau aggregation inhibitor (TAI) currently in three large global Phase 3 clinical trials.
The Journal of Alzheimer’s Disease has published today the results of the first clinical trial of a Tau Aggregation Inhibitor (TAI) in Alzheimer’s disease (AD). This Phase II clinical trial, conducted by TauRx Therapeutics Ltd (a Singapore incorporated spinout from the University of Aberdeen), provided the basis and rationale for subsequent Phase III clinical trials of a TAI in AD currently in progress.
TauRx Therapeutics Achieves Enrolment Target for Second Phase III Clinical Trial of LMTX™ in Alzheimer’s Disease
TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer’s disease into the second of its two Phase III clinical trials of LMTX™, a tau aggregation inhibitor, for the treatment of Alzheimer’s disease.
TauRx Therapeutics Achieves Enrolment Target in the First of its Two Phase III Clinical Trials of LMTX™ in Alzheimer’s Disease
TauRx Therapeutics Ltd today announced it has achieved its target enrolment of 833 subjects into one of its two ongoing multi-centre Phase III clinical trials of LMTX™, a tau aggregation inhibitor, for the treatment of Alzheimer’s Disease [AD].
Prof. Wischik, Chairman of TauRx Therapeutics, will present a scientific update at the 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy on the company’s global Phase 3 clinical trials; its tau aggregation inhibitor, LMTX™, is aimed at halting the progression of Alzheimer’s
TauRx Chairman and London-based principal investigator will highlight how access to investigational treatments for Alzheimer’s is changing the care model for people with cognitive impairment – now and in the future
Erste deutsche Patienten melden sich zu den klinischen Phase-3-Studien von LMTX™ zur Alzheimer-Krankheit an
Klinische Studien beginnen in Deutschland mit einem Tau-Aggregationshemmer (TAI) der zweiten Generation mit dem Ziel, das Fortschreiten von Alzheimer zu stoppen
Clinical trials get under way in Germany with a second-generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer’s
Clinical research centers added to allow more patients to access a tau-based investigational treatment for mild to moderate Alzheimer’s disease